Natera, Inc. suffered a setback as the U.S. District Court invalidated claims in patents asserted against NeoGenomics’ RaDaR v1.1 test. The company is considering an appeal or other enforcement actions. However, the ruling does not impact the ‘035 patent, which previously led to injunctions against NeoGenomics’ RaDaR v1.0 product. With over 500 patents, Natera remains committed to protecting its innovations. Shares of NTRA are up 0.19% on the NasdaqGS, currently trading at $168.25. The company reaffirmed its dedication to defending its intellectual property and advancing its technological capabilities.

Read more at NASDAQ: Natera Updates On Patent Ruling In Litigation With NeoGenomics